Graveyard / Equity events / US stocks
Buying new spin-off stocks
Do newly spun-off companies outperform after they list?
The idea
When a parent company spins off a subsidiary, shareholders who never chose it (index funds, mandate-bound funds) sell without caring about price. The new stock should then be cheap and recover over one to three years.
How we tested it
| Data | Spin-offs identified from Form 10-12B filings with a NYSE or Nasdaq ticker, plus 15 delisted spin-offs mapped by hand, with daily prices. Close at least $5 and dollar volume at least $5M on listing day. Buy at the first close, hold 250 sessions, short an equal dollar amount of IWM, 30 slots. |
|---|---|
| Period | July 2019 to October 2026, split at 25 April 2025. |
| Costs | 10 bp per side plus 1 bp on the hedge; stress at 1.5x. |
| Holdout | Full-period Sharpe, in-sample Sharpe and out-of-sample profit factor all had to pass. |
| Control | No random-entry control was run. An event study of average returns by horizon is reported. |
Result
| Trades | 51 |
|---|---|
| Sharpe, full period | 0.64 |
| Sharpe in-sample | 0.31 |
| Out-of-sample Sharpe / profit factor | 1.96 / 1.11 |
| Profit factor | 3.77 |
| Max drawdown | −15% |
| Mean vs median trade | +43% vs +3.4% |
| Largest winner | +1,635% vs IWM |
| Event study, 20 / 60 days | −0.7% / −1.4% |
| Sharpe in bull / bear / chop markets | 1.66 / −1.15 / 0.43 |
Why it failed
It failed the Sharpe and out-of-sample bars. The mean of +43% is one lottery ticket: a single memory-chip spin-off in 2025 returned +1,635% and carries the average, while the median trade made +3.4%. The early weeks after listing are negative, which fits index-holder selling. Spin-offs that were acquired or failed may be missing from the sample.
What would make it worth retesting
A variant that waits 20 sessions after listing looked better (+14.9% over 125 sessions, t 3.0, 54 events), but it was picked after seeing the data. It needs a pre-registered test on independent data (2005-2018 spin-offs with delisted names) plus new listings from late 2026.
Past results of a backtest say nothing certain about the future.